Guangzhou, China

Shujun Pei

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Bio-Thera Solutions, Ltd.. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shujun Pei. Retrieved from https://idiyas.com/inventor/shujun-pei

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Shujun Pei: Innovator in Antibody Research

Introduction

Shujun Pei is a notable inventor based in Guangzhou, China. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies. His work is instrumental in advancing therapeutic options for various diseases.

Latest Patents

Shujun Pei holds a patent for an invention titled "Antibody Binding to PD-1." This innovative patent is crucial for understanding and potentially treating conditions related to immune response.

Career Highlights

Pei is currently employed at Bio-Thera Solutions, Ltd., a company dedicated to developing innovative biopharmaceuticals. His role at the company allows him to apply his expertise in antibody research to real-world applications.

Collaborations

Throughout his career, Shujun Pei has collaborated with talented individuals such as Haitao Yue and Jian Lin. These partnerships enhance the research and development efforts at Bio-Thera Solutions, Ltd.

Conclusion

Shujun Pei's contributions to antibody research exemplify the impact of innovation in biotechnology. His work continues to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…